<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BENZTROPINE MESYLATE- benztropine mesylate injection </strong><br>TYA Pharmaceuticals<br></p></div>
<h1>Benztropine Mesylate Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine.</p>
<p>It is designated chemically as 8-azabicyclo[3.2.1] octane, 3-(diphenylmethoxy)-, , methanesulfonate. Its empirical formula is C H NO•CH O S, and its structural formula is:
                            <span class="Italics">endo</span><span class="Sub">21</span><span class="Sub">25</span><span class="Sub">4</span><span class="Sub">3</span></p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d61eae0d-a29d-45ef-bd41-07123e0c21f9&amp;name=ben06-0002-01.jpg">
</div>
<p>Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54.</p>
<p>Benztropine mesylate injection, USP is supplied as a sterile injection for intravenous and intramuscular use.</p>
<p>Each milliliter of the injection contains:</p>
<p>Benztropine mesylate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 mg</p>
<p>Sodium chloride . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 mg</p>
<p>Water for injection q.s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 mL</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Benztropine mesylate injection, USP possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>.</p>
<p>In the isolated guinea pig ileum, the anticholinergic activity of this drug is about equal to that of atropine; however, when administered orally to unanesthetized cats, it is only about half as active as atropine.</p>
<p>In laboratory animals, its antihistaminic activity and duration of action approach those of pyrilamine maleate.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">For use as an adjunct in the therapy of all forms of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> (see ).
                            <a href="#s12">DOSAGE AND ADMINISTRATION</a></p>
<p>Useful also in the control of <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span> (except <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> – see ) due to neuroleptic drugs (e.g., phenothiazines).
                            <a href="#s7">PRECAUTIONS</a></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of benztropine mesylate injection, USP.</p>
<p>Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Safe use in pregnancy has not been established.</p>
<p>Benztropine mesylate injection, USP may impair mental and/or physical abilities required for performance  of hazardous tasks, such as operating machinery or driving a motor vehicle.</p>
<p>When benztropine mesylate injection, USP is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or heat  intolerance promptly. <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> and <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate injection, in   combination with phenothiazines and/or tricyclic antidepressants.</p>
<p>Since benztropine mesylate injection contains structural features of atropine, it may produce <span class="product-label-link" type="condition" conceptid="140490" conceptname="Anhidrosis">anhidrosis</span>. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment. <span class="product-label-link" type="condition" conceptid="140490" conceptname="Anhidrosis">Anhidrosis</span> may occur more readily when some disturbance of <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> already exists. If there is evidence of <span class="product-label-link" type="condition" conceptid="140490" conceptname="Anhidrosis">anhidrosis</span>, the possibility of <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe <span class="product-label-link" type="condition" conceptid="140490" conceptname="Anhidrosis">anhidrosis</span> and fatal <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> have occured.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s8"></a><a name="section-7.1"></a><p></p>
<p class="First">Since benztropine mesylate injection, USP has cumulative action, continued supervision is advisable. Patients with a tendency to <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and patients with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> should be observed closely during treatment.
                                    <span class="Bold">General:</span></p>
<p><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span> may occur, but rarely becomes a problem. <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> has been reported with benztropine mesylate injection, USP.</p>
<p>The drug may cause complaints of <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and inability to move particular muscle groups, especially in large doses. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event, dosage adjustment is required.</p>
<p><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Mental confusion</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> may occur with large doses, or in susceptible patients. <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">Visual hallucinations</span> have been reported occasionally. Furthermore, in the treatment of <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span> due to neuroleptic drugs (e.g., phenothiazines), in patients with <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">mental disorders</span>, occasionally there may be intensification of mental symptoms. In such cases, antiparkinsonian drugs can precipitate a toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. Patients with <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">mental disorders</span> should be kept under careful observation, especially at the beginning of treatment or if dosage is increased.</p>
<p><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> may appear in some patients on long-term therapy with phenothiazines and related agents, or may occur after therapy when these drugs have been discontinued. Antiparkinsonism agents do not alleviate the symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, and in some instances may aggravate them. Benztropine mesylate injection, USP is not recommended for use in patients with <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>.</p>
<p>The physician should be aware of the possible occurrence of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Although the drug does not appear to have any adverse effect on simple <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, it probably should not be used in angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s9"></a><a name="section-7.2"></a><p></p>
<p class="First">Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants (see ).
                                    <span class="Bold">Drug Interactions:</span><a href="#s6">WARNINGS</a></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s10"></a><a name="section-7.3"></a><p></p>
<p class="First">Because of the atropine-like side effects, benztropine mesylate injection, USP should be used with caution in pediatric patients over three years of age (see ).
                                    <span class="Bold">Pediatric use:</span><a href="#s5">CONTRAINDICATIONS</a></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="e10"></a><a name="section-7.4"></a><p></p>
<p class="First">Clinical studies of benztropine mesylate did not include sufficient numbers of subjects aged 65 and over to determine whether may respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should start at the low end of the dosing range (see ) and the dose should be increased only as needed with monitoring for the emergence of adverse events (see and ).
                                    <span class="Bold">Geriatric Use:</span><a href="#s12">DOSAGE AND ADMINISTRATION</a><a href="#s7">PRECAUTIONS</a><a href="#s11">ADVERSE REACTIONS</a></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s11"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The adverse reactions below, most of which are anticholinergic in nature, have been reported and within each category are listed in order of decreasing severity.</p>
<p><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>.
                            <span class="Bold">Cardiovascular:</span></p>
<p><span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.
                            <span class="Bold">Digestive:</span></p>
<p>If <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily.</p>
<p>Slight reduction in dosage may control <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and still give sufficient relief of symptoms. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> may be controlled by temporary discontinuation, followed by resumption at a lower dosage.</p>
<p>Toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, including <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>; exacerbation of pre-existing <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">listlessness</span>; <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness of fingers</span>.
                            <span class="Bold">Nervous System:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>.
                            <span class="Bold">Special Senses:</span></p>
<p><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>.
                            <span class="Bold">Urogenital:</span></p>
<p>Occasionally, an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, develops. If this cannot be controlled by dosage reduction, the medication should be discontinued.
                            <span class="Bold">Metabolic/Immune or Skin:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">Heat stroke</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.
                            <span class="Bold">Other:</span></p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Akorn, Inc. at 1-800-932-5676 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s12"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Since there is no significant difference in onset of effect after intravenous or intramuscular injection, usually there is no need to use the intravenous route. The drug is quickly effective after either route, with improvement sometimes noticeable a few minutes after injection. In emergency situations, when the condition of the patient is alarming, 1 to 2 mL of the injection normally will provide quick relief. If the parkinsonian effect begins to return, the dose can be repeated.</p>
<p>Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five or six-day intervals to the smallest amount necessary for optimal relief. Increases should be made in increments of 0.5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-9.1"></a><p></p>
<p class="First">The following dosing guidelines were written in reference to both benztropine mesylate tablets and COGENTIN Injection. Benztropine mesylate tablets should be used when patients are able to take oral medication.
                                    <span class="Bold">Postencephalitic and Idiopathic <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>:</span></p>
<p>The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg parenterally.</p>
<p>As with any agent used in <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, dosage must be individualized according to age and weight, and the type of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> being treated. Generally, older patients, and thin patients cannot tolerate large doses. Most patients with postencephalitic <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> need fairly large doses and tolerate them well. Patients with a poor mental outlook are usually poor candidates for therapy.</p>
<p>In idiopathic <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, therapy may be initiated with a single daily dose of 0.5 to 1 mg at bedtime. In some patients, this will be adequate; in others 4 to 6 mg a day may be required.</p>
<p>In postencephalitic <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, therapy may be initiated in most patients with 2 mg a day in one or more doses. In highly sensitive patients, therapy may be initiated with 0.5 mg at bedtime, and increased as necessary.</p>
<p>Some patients experience greatest relief when given the entire dose at bedtime; others react more favorably to divided doses, two to four times a day. Frequently, one dose a day is sufficient, and divided doses may be unnecessary or undesirable.</p>
<p>The long duration of action of this drug makes it particularly suitable for bedtime medication when its effects may last throughout the night, enabling patients to turn in bed during the night more easily, and to rise in the morning.</p>
<p>When benztropine mesylate injection, USP is started, do not terminate therapy with other antiparkinsonian  agents abruptly. If the other agents are to be reduced or discontinued, it must be done gradually. Many patients obtain greatest relief with combination therapy.</p>
<p>Benztropine mesylate injection, USP may be used concomitantly with, SINEMET (Ccarbidopa-Levodopalevodopa), or with levodopa, in which case dosage adjustment may be required in order to maintain optimum response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-9.2"></a><p></p>
<p class="First">In treating <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span> due to neuroleptic drugs (e.g., phenothiazines), the recommended dosage is 1 to 4 mg once or twice a day parenterally. Dosage must be individualized according to the need of the patient. Some patients require more than recommended; others do not need as much.
                                    <span class="Bold">Drug-Induced <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Disorders</span>:</span></p>
<p>In acute <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>, 1 to 2 mL of the injection usually relieves the condition quickly.</p>
<p>When <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span> develop soon after initiation of treatment with neuroleptic drugs (e.g., phenothiazines), they are likely to be transient. One to 2 mg of benztropine mesylate injection, USP two or three times a day usually provides relief within one or two days. If such disorders recur, COGENTIN can be reinstituted.</p>
<p>Certain drug-induced <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span> that develop slowly may not respond to benztropine mesylate injection, USP.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s15"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-10.1"></a><p></p>
<p class="First">May be any of those seen in atropine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> or antihistamine overdosage: <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, preceded or followed by stimulation; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">listlessness</span>; intensification of mental symptoms or toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> in patients with mental illness being treated with neuroleptic drugs (e.g., phenothiazines); <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (especially visual); <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>; <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>; <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>; <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>; <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; elevated blood pressure; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>; <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness of fingers</span>; <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; hot, dry, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed skin</span>; <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>; <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>; <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>; <span class="product-label-link" type="condition" conceptid="140490" conceptname="Anhidrosis">anhidrosis</span>; <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>; <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>; <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.
                                    <span class="Bold">Manifestations:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-10.2"></a><p></p>
<p class="First">Physostigmine salicylate, 1 to 2 mg, SC or IV, reportedly will reverse symptoms of anticholinergic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.** A second injection may be given after 2 hours if required. Otherwise treatment is symptomatic and supportive. Maintain respiration. A short-acting barbiturate may be used for CNS <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, but with caution to avoid subsequent <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; supportive care for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (avoid convulsant stimulants such as picrotoxin, pentylenetetrazol, or bemegride); artificial respiration for severe <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>; a local miotic for <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> and <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>; ice bags or other <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> applications and alcohol sponges for <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, a vasopressor and fluids for <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>. Darken room for <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>.
                                    <span class="Bold">Treatment:</span></p>
<p>** Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. : 1963-1965, Nov. 25, 1968
                                    <span class="Italics">206</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s18"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NDC:64725-0012-1 in a CARTON of 5 INJECTIONS</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s19"></a><a name="section-11.1"></a><p></p>
<p class="First">Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature].
                                    <span class="Bold">Storage:</span></p>
<p>Akorn</p>
<p>Distributed by:
                                    <span class="Bold">Akorn, Inc.</span></p>
<p>Lake Forest, IL 60045</p>
<p>BZ00N Rev. 05/13</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>BENZTROPINE MESYLATE INJECTION</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d61eae0d-a29d-45ef-bd41-07123e0c21f9&amp;name=64725-0012.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BENZTROPINE MESYLATE 		
					</strong><br><span class="contentTableReg">benztropine mesylate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64725-0012(NDC:17478-012)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Benztropine Mesylate</strong> (Benztropine) </td>
<td class="formItem">Benztropine Mesylate</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64725-0012-1</td>
<td class="formItem">5 mL in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA012015</td>
<td class="formItem">08/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>TYA Pharmaceuticals
							(938389038)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>TYA Pharmaceuticals (938389038)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">TYA Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">938389038</td>
<td class="formItem">RELABEL(64725-0012), REPACK(64725-0012)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9573c6b0-a783-4559-8e44-74ee89fc28a2</div>
<div>Set id: d61eae0d-a29d-45ef-bd41-07123e0c21f9</div>
<div>Version: 2</div>
<div>Effective Time: 20130531</div>
</div>
</div> <div class="DistributorName">TYA Pharmaceuticals</div></p>
</body></html>
